Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00341991 · ClinicalTrials.gov registry record

Molecular Epidemiology of Cutaneous Malignant Melanoma

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
15,401
Enrollment target

NCT00341991: Completed study, sponsored by National Cancer Institute (NCI).

NCT00341991 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 15,401 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00341991 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
15,401 participants
Enrollment target

Study Summary

This case-control study was planned to investigate the link of solar radiation with gene damage, host factors, and DNA repair proficiency in cutaneous malignant melanoma (CMM) risk. The hypothesis was that impaired DNA repair proficiency is associated with an increased risk of CMM due to unrepaired DNA damage, particularly in subjects with dysplastic nevi, poor tanning ability or genetic susceptibility. The study was reviewed as an RO1 Grant from the National Cancer Institute in 1995. Subject enrollment, which included clinical evaluation, epidemiologic questionnaires, and skin and blood sample collection, was completed in 1999 on approximately 180 melanoma cases and 180 controls identified in Italy. The study protocol and consent form both included the measurement of genetic and biochemical factors and DNA repair capacity. DNA repair proficiency was measured in lymphocytes by the host cell reactivation assay, and sun exposure was evaluated by means of a detailed questionaire. Photographs of the back of the subjects were taken to allow nevi count. Minimal erythemal dosage was measured in all subjects to estimate skin sun sensitivity 24 hours after skin's UV-irradiation. Skin color was ascertained on the inner side of the forearm by means of a Minolta chromometer. The aim of this protocol is to continue analysis of the biological samples already collected, as originally outlined in the study protocol. In particular, we plan to measure polymorphisms in genes that may lead to susceptibility to melanoma. Initially we will concentrate on variation in genes involved in repairing damaged DNA, but plan to look at a broad group of candidate susceptibility genes.

Trial Details

FieldValue
Enrollment Target 15,401 participants
Start Date 2001-11-01
Est. Completion 2020-06-26

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00341991

The ClinicalTrials.gov registry entry for NCT00341991 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 15,401 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00341991 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00341991 about?

NCT00341991 is a clinical study titled "Molecular Epidemiology of Cutaneous Malignant Melanoma". This case-control study was planned to investigate the link of solar radiation with gene damage, host factors, and DNA repair proficiency in cutaneous malignant melanoma (CMM) risk. The hypothesis was that impaired DNA repair proficiency is associated with an increased risk of CMM due to unrepaired ...

What is the current status of trial NCT00341991?

This trial is currently completed. The enrollment target is 15,401 participants. The study started on 2001-11-01. Estimated completion is 2020-06-26.

Who is sponsoring clinical trial NCT00341991?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.